Chimeric receptors that link ligand recognition domains, such as antibody Fv fragments, with TCR signaling domains can redirect T lymphocytes against MHC-unrestricted targets. Such receptor-modified T lymphocytes have shown promise in the treatment of infectious diseases and cancer. We hypothesized that receptor-modified T lymphocytes may also be designed to target antigen-specific T cells. We synthesized chimeric receptors consisting of the extracellular and transmembrane domains of the class I MHC H-2K b molecule linked to the signaling domains of either TCR-z, CD28 and z, or CD28, z, and lck. T lymphocytes modified to express these receptors and pulsed with antigenic peptide specifically killed precursor CTL. Cytolysis was efficient, even at effector:target ratios of less than one, and specific, selectively killing antigen-specific precursor CTL among a mixed population of T cells. Cytolysis required activation of the receptormodified T cells, and did not occur with a signaling-deficient chimeric receptor. In contrast to precursor CTL, differentiated CTL proved resistant to lysis by the receptor-modified T cells. These data demonstrate the feasibility of redirecting T lymphocytes against antigen-specific T cells. Receptormodified T cells expressing chimeric MHC receptors have potential application in autoimmune and alloimmune diseases.
Introduction
The induction of antigen-specific immune tolerance is a primary goal in the immunotherapy of autoimmune diseases and transplant rejection, and in the engineering of bone marrow grafts. Although various approaches have been tested to achieve this goal, such as the use of tolerizing regimens of antigen [1] [2] [3] and the veto effect, 4, 5 none has been clinically validated yet. Cellular immunotherapy using T lymphocytes would seem promising for inducing antigen-specific immune tolerance. 6 T cells possess many effector and regulatory functions that could be appropriated for therapeutic use. The migratory properties of immunotherapeutic T cells would be expected to mimic that of their targets. Further, adoptively transferred therapeutic T cells can survive for greater than 1 year within a host. 7 Indeed, administration of antigen-specific T lymphocytes has shown promise in the treatment of infectious diseases and tumors. [8] [9] [10] The antigen specificity of a pathologic T cell is predefined by the cell's TCR, which is rearranged and selected during thymic development. A critical challenge is to develop immunotherapeutic T lymphocytes that can target based on this TCR specificity. Such TCR-specific targeting should be possible. Several studies have demonstrated that surrogate TCRs that link ligandbinding domains to TCR activation domains can be constructed, and that these redirect T cells against MHCunrestricted antigens. 6, [11] [12] [13] We reasoned that chimeric receptors that link antigen-MHC complexes to activation domains of the TCR could similarly redirect T cells against other T cells of predefined antigen specificity, inverting the essentially reciprocal relation between a T cell and its APC. Engagement of the chimeric receptor on a receptormodified T cell by the TCR of an antigen-specific T cell would be expected to stimulate the receptor-modified T cell, inducing therapeutic effector functions.
In order to test this concept, we generated a series of chimeric receptors containing the murine class I MHC molecule H-2K b linked to a variety of T-cell signaling domains. In a previous study, we demonstrated that such chimeric receptors were capable of effectively transducing signals into T-cell hybridomas, and that the biochemical nature of the transduced signal was dependent upon the constituent components of the signaling tail. 14 In this study, we show that chimeric receptors linking K b with different signal transduction domains can redirect CTL in an antigen-specific manner against CD8 + T cells. The potency of the receptor-modified T cells was independent of the activation domain of the chimeric receptor. The susceptibility of the CD8 + target cell to lysis, however, was dependent upon the target cell's activation state.
transmembrane domains linked to the cytoplasmic tails of TCR-z (K b -z), CD28 and z (K b -CD28-z), CD28, z, and lck deleted of its membrane attachment domain (K b -CD28-z-lck), or lacking a signaling domain (K b ).
14 These constructs were subcloned into the MSCV-I-GFP retroviral vector, which coexpresses GFP in a bicistronic message. Retrovirally transduced T cells were sorted for expression of CD8 and GFP and then stained with H-2K were stimulated and transduced with retroviral supernatants. Primary transductants were flow cytometrically sorted for the expression of GFP and CD8. Sorted cell lines were expanded and stained for chimeric receptor expression using the H-2K
b -specific antibody AF6-88.5.
To determine whether the chimeric receptors were able to transduce functional signals, we stimulated the receptor-modified cell lines with either K b -specific or control CD3e-specific antibodies and measured proliferative response (Figure 2 ). Each T-cell line that included a signal transduction domain ( (Figure 2a) . Control cell lines transduced with empty MSCV-I-GFP vector or with a signalingdeficient chimeric receptor (K b ) failed to respond. All Tcell lines responded vigorously to CD3e-specific antibody, demonstrating that cellular expression of the chimeric receptors did not interfere with signaling through the cells' endogenous TCR (Figure 2b ). These results show that the chimeric receptors are expressed on and functionally signal the retrovirally transduced T lymphocytes.
T-cell cytotoxicity mediated by chimeric receptors
To test whether the receptor-modified T cells could target T cells expressing low-affinity antigen-specific TCR, we analyzed directed cytolysis against antigen-specific T cells. We pulsed the receptor-modified T cell lines with the 257-264 peptide fragment from ovalbumin, and then cocultured them with freshly isolated OT-1 TCR transgenic lymph node cells. OT-1 T cells are specific for H-2K b , present on the chimeric receptor, associated with this ovalbumin peptide. After 6 h of coculture, we quantitatively measured absolute numbers of residual OT-1 T cells by flow cytometry (Figure 3 ). Control MSCV vector-transduced T cells and signal-domain-deficient K b -transduced T cells showed similar numbers of residual OT-1 T cells after culture, regardless of whether the receptor-modified T cells were pulsed with antigenic peptide (Figure 3a-d) . This demonstrates that there was no antigen-specific killing of OT-1 T cells by these control cell lines. Indeed, there was no loss of OT-1 T cells in these cultures when compared with OT-1 cultures in which receptor-modified T cells were not added, demonstrating that the control receptor-modified T cell lines did not affect OT-1 T cell numbers (data not shown). In the case of the control K b chimeric receptor, although the target OT-1 cells were not lysed, surface Va2, and therefore TCR, expression was downmodulated ( Figure  3d ). Since TCR downmodulation follows TCR stimulation, 15 Receptor-Modified T cells P Nguyen and TL Geiger In any therapeutic effort to ablate antigen-specific T cells, the desired target cells will represent only a small subpopulation of total T lymphocytes. In order to determine whether the receptor-modified T cells could distinguish such a subset of antigen-specific cells, we mixed purified OT-1 and nontransgenic B6 T cells at a ratio of 1:20. After coincubation for 6 h with receptormodified T cells at an effector to total target cells ratio of 0.33:1 we measured residual OT-1 T and B6 T cells. OT-1 T cells were selectively targeted and bystander lysis of the B6 cells was not seen ( Figure 5 ). This demonstrates that the receptor-modified T cells were able to discriminately kill CD8 + T cells in a mixed culture based on TCR specificity.
Cytolysis of stimulated OT-1 T cells
The results above demonstrate specific cytolysis of primary T cells. Stimulated T cells may be more difficult to target. Whereas some studies have demonstrated fratricidal lysis of CTL, other studies have shown that CTL are intrinsically resistant to cytolysis. [17] [18] [19] [20] [21] [22] [23] Our experimental system, however, differs from prior studies analyzing the killing of CTL by other CTL. When the receptor-modified T cell is stimulated through its chimeric receptor by the OT-1 target T cell, the OT-1 T cell is simultaneously stimulated through its TCR. If the OT-1 T cell has matured into a CTL, both that and the receptor-modified T cell would be expected to activate their lytic machinery. Three possible consequences of this mutual activation could be anticipated; death of both the OT-1 and the receptor-modified T cell, death of only one of the T cells, and survival of both T cells.
To test for cytotoxicity against activated T lymphocytes, we generated an OT-1-derived CD8 + CTL line and analyzed cytotoxicity by the receptor-modified T cells ( Figure 6 ). Analyses were performed at 6 and 20 h time points and compared with analyses of the killing of primary OT-1 T cells at similar time points. As described above, the K Receptor Receptor-Modified T cells P Nguyen and TL Geiger was observed with the K b control receptor-modified T cells, showing that the signaling tail of the chimeric receptors was not required for this activity.
At the 20 h time point, the result of coculture of OT-1 and peptide-pulsed receptor-modified T cells was variable between individual experiments, but overall failed to demonstrate specific killing by any of the receptormodified T-cell lines (Figure 6d) . The increased variability in assay results at this late time point was likely because of the interplay of many factors affecting residual OT-1 CTL numbers after prolonged culture. These include death because of the withdrawal of exogenously added IL-2 during the lysis assay, killing by receptor-modified T cells, activation-induced cell death, and stimulation of proliferation or survival among the OT-1 T cells by receptor-modified T-lymphocyte peptide presentation or carryover. On average, survival promotion or proliferation predominated and there was an increase in OT-1 T-cell number at the 20 h time point compared with control cocultures in which the receptormodified cells were not peptide pulsed.
One possible explanation for the failure of the receptor-modified T cells to kill the OT-1 CTL line is that the receptor-modified T lymphocytes were themselves killed by the OT-1 CTL. Analyses of survival of the receptor-modified T cells after 6 and 20 h cocultures, however, excluded this possibility and indicated that both the receptor-modified T cell and the target OT-1 CTL lines were equivalently resistant to lysis (data not shown).
One report shows that CTL may be functionally tolerized by exposure to MHC-peptide on other CTL. In this analysis, the tolerized CTL lost their ability to specifically kill target cells. 24 To test whether the receptor-modified T cells could similarly tolerize OT-1 CTL, we cocultured peptide-pulsed receptor-modified T cells with OT-1 CTL. After 20 h, we flow cytometrically sorted OT-1 CTL and cocultured them with ova257-264-pulsed or unpulsed target cells. Lysis by the OT-1 CTL precultured with peptide-pulsed receptor-modified T cells did not substantially differ from that of the OT-1 CTL precultured with MSCV vector transfected controls ( Figure 7) . The receptor-modified T cells were therefore unable to kill or otherwise tolerize mature OT-1 CTL.
In order to define the developmental timing of the acquisition of resistance to lysis, we stimulated primary OT-1 T cells with CD3e-specific antibody and irradiated APCs at various time points. We then harvested and tested the T cells for susceptibility to killing by the ova257-264-pulsed receptor-modified T lymphocytes. Resistance to lysis developed between 3 and 7 days after T-cell stimulation (Figure 8) . By 7 days, most target cells were refractory to the activity of the receptor-modified T cells. This time frame coincides with the known kinetics of maturation of CTL precursors into CTL, 25 implying that resistance to lysis by the receptor-modified T lymphocytes is acquired in conjunction with OT-1 T-cell differentiation into CTL.
Discussion
This study describes a new approach to antigenspecifically target T lymphocytes. We demonstrate that chimeric receptors that link class I MHC molecules to signal transduction domains derived from the TCR z chain, CD28, and/or lck can be expressed on retrovirally transduced T lymphocytes. Precursor CTL-antigen specifically engage the chimeric receptor on transduced CTL, thereby activating the receptor-modified T cell. The receptor-modified cell is then able to kill the target T cell. Cytolysis is efficient, occurring at effector-to-target ratios of less than one. Cytolysis of precursor-CTL requires the activation of the receptor-modified T lymphocyte, as a chimeric receptor lacking a signaling domain does not mediate cytolysis. As target CD8 + T cells mature into Receptor-Modified T cells P Nguyen and TL Geiger CTL, they acquire resistance to lysis by the receptormodified T cells.
Receptor-modified T lymphocytes have potential application in several arenas in which the deletion of antigen-specific T cells is desirable. Bone marrow grafts depleted of host major or minor histocompatibility antigen-specific T cells would be expected to minimize the risk of graft-versus-host disease. 26, 27 Treatment of grafts prior to transplant with receptor-modified T lymphocytes expressing chimeric receptors that incorporate host MHC should eliminate these alloantigenspecific T cells, thereby improving graft compatibility. Similarly, pretreatment of transplant recipients in vivo with receptor-modified T lymphocytes presenting graft alloantigens would be expected to eliminate host antigraft T lymphocytes. This could decrease the likelihood of graft rejection and diminish the requirement for immunosuppressive drugs after transplantation. Receptor-modified T cells may be pulsed with alloantigenic peptides to direct them against T cells with particular allospecificities. Alternatively, endogenous peptides may associate with the chimeric receptor's allogeneic MHC, permitting the deletion of alloantigen-specific T cells. T cells specific for endogenous peptides, however, will have a broad specificity range that may include pathologically insignificant as well as significant T-cell clones.
The use of receptor-modified T lymphocytes to induce allotolerance would be complex, requiring personalized regimens using autologous transduced T lymphocytes. However, the clinical use of receptor-modified T cells has been tested in phase I trials in other circumstances. T cells expressing chimeric receptors specific for HIV or for the CD20 B-cell antigen have been reported to be non-toxic and to persist for several months. 7, 28 This implies that receptor-modified T cells expressing MHC or MHCpeptide ligands may be equivalently nontoxic when applied in vivo.
In contrast to an unprimed immune repertoire, our studies suggest that receptor-modified T cells may be ineffective in an immune system that is antigen experienced. We show that differentiated CTL are not effectively eliminated by receptor-modified T lymphocytes. After 6 h of coculture, there is a trend toward decreased target cell numbers that is not dependent upon activation of the receptor-modified T cells. If true, Receptor-Modified T cells P Nguyen and TL Geiger this may result from Fas-mediated CTL death after ligand engagement, as has been observed by others. 29 However, by 20 h target cell numbers rebound to levels at or above that of controls, suggesting that cognate antigen presented by the receptor-modified T cells, while possibly inducing cell death among target T cells early on, ultimately promotes their expansion.
Whether an enhancement of the lytic activity of receptor-modified T cells against target CTL is possible will require further study. Indeed, although numerous studies have shown that CTL are relatively unsusceptible to lysis by other CTL, 19, 21, 23 several reports demonstrate that this resistance is not absolute. Thus, fratricidal lysis of virally infected or peptide-pulsed CTL has been described by several groups. 17, 18, 30, 31 . Fratricidal lysis of CTL, however, is inefficient compared to CTL lysis of other target cells. CTL lysis resistance may result from multiple factors, including the expression of granzymeinhibitory serpins and refractoriness to perforin binding. 20, 22, 32 An improved understanding of the mechanism of T-cell resistance to lysis and of fratricidal lysis will be useful in engineering receptor-modified T cells able to better target mature CTL.
If receptor-modified T cells cannot eliminate activated CTL, they would seem to be of limited use in immunopathologic processes in which CTL have a significant role, such as active autoimmune diseases, GVHD, or graft rejection. However, receptor-modified T cells may still have application in these settings. Although CD8 + CTL develop resistance to lysis, activated CD4 + T cells remain susceptible. We have shown that CTL genetically modified to express class II MHC molecules linked to TCR signaling domains are able to target immunopathologic CD4 + T lymphocytes (D Mekala and T Geiger, unpublished observations). Further, the chimeric receptors described here provide a mechanism to antigen-specifically stimulate receptor-modified T lymphocytes. They do not define the effector functions that are triggered by that stimulation. Cytolysis, studied here, comprises only one such effector function. Receptor-modified immunoregulatory subsets of CD8 + or CD4 + T cells, including those producing TGFb or other immunoregulatory cytokines, may inhibit pathologic CTL, even if it is not possible to lyse them. 33, 34 Although chimeric receptor types with different signaling domains were tested in these studies, none proved superior in stimulating receptor-modified T-cell function. This observation was unexpected as we have previously shown that the K In summary, we provide a novel approach to selectively target antigen-specific T cells using receptormodified T lymphocytes. These initial studies demonstrate the feasibility and limitations of creating CD8 + receptor-modified T lymphocytes expressing and applying chimeric MHC-z receptors. They provide a basis for future analyses of how receptor-modified T lymphocytes may best be applied to induce antigen-specific tolerance in clinical settings.
Materials and methods

Constructs
Synthesis and sequences of the chimeric constructs are as described. 14 Briefly, cDNA fragments encoding the extracellular and transmembrane domain of the H-2K b molecule, the cytoplasmic tails of CD28 and z, and the p56 lck gene excluding the membrane proximal SH4 domain were isolated by PCR from cDNA clones or splenic cDNA. Flanking restriction sites were added to the fragments by PCR, and the fragments linked. Assembled constructs were subcloned into the MSCV-I-GFP (gift of E Vanin) 35 retroviral vector.
Mice, cells, and antibodies
TG-B mice, 36 transgenic for a rearranged SV40-T/H-2K k restricted TCR, were bred 420 generations with B10.BR mice and used as a source of CD8 + T cells for receptormodified T lymphocytes. OT-1 mice (Jackson Laboratories, Bar Harbor, ME, USA), transgenic for a rearranged ovalbumin 257-264/H-2K b restricted TCR, were used as a source of target cells. CTL lines were produced from isolated OT-1 CD8 + T cells stimulated with 2 mg/ml con A or anti-CD3e and anti-CD28 hybridoma supernatant in the presence of 2500 rad irradiated syngeneic splenocyte feeders and 2 ng/ml recombinant murine IL-2 (rmIL-2; R&D Systems, Minneapolis, MN, USA). Cultures were supplemented with 2 ng/ml rmIL-2 biweekly and restimulated every 9-10 days. Cells were analyzed at or greater than 5 days after restimulation unless otherwise indicated. Antibodies used include: clone B20.1 antimouse Va2 (Pharmingen); clone 2C11 anti-mouse CD3e; clone AF6-88.5 anti-mouse H-2K b (Pharmingen and gift of M Blackmann); goat anti-mouse IgG (Pharmingen); and goat anti-rat IgG (Pharmingen).
Retroviral transduction and T-cell culture
Retrovirus was produced as described. 37 Briefly, 10 mg of chimeric receptor constructs and 10 mg of the retrovirus helper DNA construct PEQPAM (gift of J Cleveland) were cotransfected into 293-T cells by calcium phosphate precipitation. At 16 h, the cells were washed and cultured in Dulbecco-modified Eagle medium (DMEM)/10% fetal calf serum (FCS) for 48 h. Supernatant was collected twice daily and used to infect GP+E86 retroviral producer cells in the presence of 6 mg/ ml polybrene. Transduced GP+E86 cells were flow cytometrically sorted for the presence of green fluorescence protein (GFP) and expanded. TG-B TCR transgenic mice were used as a source of enriched CD8 + T lymphocytes for retroviral transduction. To transduce T lymphocytes, isolated lymph node cells were depleted of B cells by panning on goat anti-mouse IgG-coated plates. The T cells were then stimulated with soluble CD3-and CD28-specific antibodies in the presence of 2 ng/ml rmIL-2 for 2 days. Medium was removed and replaced with cleared supernatant from the GP+E86 retroviral producer cells with 6 mg/ml polybrene and the cells were spun at 1800 rpm for 90 min in a Jouan CR422 tabletop centrifuge. A second cycle of infection was repeated on day 3. Transduced T cells were then sorted for expression of GFP and CD8 and expanded by culturing in EHAA medium (Biosource International, Camarillo, CA, USA) in the presence of rmIL-2 for 5 days. The cells were restimulated every 7-10 days using 2 mg/ml conA, 2 Â 10 6 /ml 3000 rad irradiated syngeneic splenocytes, and 2 ng/ml rmIL-2. Transduced cells were washed and assayed 4-6 days after stimulation unless otherwise indicated. Assays were performed in the absence of exogenously added IL-2.
Proliferation AF6-88.5 or 2C11 hybridoma supernatant was loaded, respectively, onto goat anti-mouse IgG or goat anti-rat IgG coated wells in 96-well plates. The designated number of transduced T cells and 5 Â 10 5 2500-rad irradiated syngeneic B10.BR splenocytes were added per well. After 2 days, the cells were pulsed with 1 mCi 
Cytotoxicity assay
Receptor-modified T cells, day 4-6 poststimulation, were incubated with or without 50 mg/ml ovalbumin 257-264 peptide (St Jude Hartwell Center for Biotechnology) or control phosphate buffered saline (PBS) diluent overnight prior to analysis, washed 3 times with PBS, and resuspended in medium. Effector cells were incubated with approximately 10 5 target cells at the designated ratio and for the designated time period. Primary T-cell targets included isolated lymph node cells or T cells purified from lymph node cells or splenocytes by panning on goat anti-mouse IgG-coated plates or by nylon wool. At 5-6 h or the designated time 5000-10 000 6 mm fluorescent TruCount beads (Becton Dickinson) were added. Samples were stained for Va2, washed once, and analyzed by flow cytometry. Viable target T cells could be distinguished from effector T cells by the presence of Va2 and the absence of GFP. Absolute target and effector cell numbers were determined by normalization of cellular events with the TruCount bead events. The fraction of residual target cells remaining after incubation (fraction control) was calculated as the absolute number of residual experimental target cells/ absolute number of control target cells. Control cultures were established in parallel with experimental cultures and contained either unpulsed receptor-modified T cells or no effector cells. All samples were analyzed in pentuplicate. In some experiments, cells were first labeled according to the manufacturer's instructions with PKH26 red fluorescent cell linker (Sigma) or carboxyfluorescein succinimidyl ester (CFSE; Molecular Probes).
Statistics
Standard deviations and paired two-sided t-tests were calculated using Excel spreadsheet software. Error bars correspond to 71s.d.
